Document is current
Any future updates will be listed below
-
Authors
Chen, Fangyuan https://orcid.org/0000-0002-9891-4753
Onkar, Sayali
Zou, Jian
Li, Yujia
Arbore, Haley
Maley, Sai
Tseng, George https://orcid.org/0000-0002-5447-1014
Lucas, Peter C.
Bruno, Tullia C.
Vignali, Dario A. A.
Foldi, Julia https://orcid.org/0000-0002-7504-867X
Balic, Marija
Lee, Adrian V. https://orcid.org/0000-0001-9917-514X
Oesterreich, Steffi
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01 CA252378)
Foundation for the National Institutes of Health (S10OD028483)
Foundation for the National Institutes of Health (R35 CA263850)
Foundation for the National Institutes of Health (P01 AI108545)
The Shear Family Foundation and Magee Womens Research Institute and Foundation
Breast Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 25 October 2024
First Online: 9 November 2024
Competing interests
: D.A.A.V.: cofounder and stock holder—Novasenta, Potenza, Tizona, Trishula; stock holder—Werewolf; patents licensed and royalties—B.M.S., Novasenta; scientific advisory board member—Werewolf, F-Star, Apeximmune, T7/Imreg Bio; consultant—B.M.S., Regeneron, Ono Pharma, Avidity Partners, Peptone; funding—B.M.S., Novasenta. Other authors declare no competing interests.
